Utilization of gene-engineered T cells for enhancing cancer immunotherapy

杀伤T淋巴细胞可以穿透肿瘤，它们转移到癌症患者体内已经显示出一些令人鼓舞的结果，但这种形式的治疗和包括疫苗接种在内的其他方法对大多数癌症患者仍然无效。在这个项目中，我们建议通过对杀伤细胞进行基因工程，使其能够识别和摧毁癌细胞，同时将对正常组织的毒性降至最低，从而改善肿瘤的运输和抗肿瘤活性。

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.